Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study

Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
doi: https://doi.org/10.1101/2021.10.29.21265248

Article Information

doi 
https://doi.org/10.1101/2021.10.29.21265248
History 
  • October 29, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Ruvim Izikson, MD1,*,
  2. Daniel Brune, MD2,
  3. Jean-Sébastien Bolduc, PhD3,
  4. Pierre Bourron, PharmD4,
  5. Marion Fournier, MSc4,
  6. Tamala Mallett Moore, MD1,
  7. Aseem Pandey1,
  8. Lucia Perez1,
  9. Nessryne Sater, PharmD3,
  10. Anju Shrestha, MD1,
  11. Sophie Wague, MSc4 and
  12. Sandrine I Samson, PhD4
  1. 1Sanofi Pasteur, Swiftwater, Pennsylvania, USA
  2. 2Accelerated Enrollment Solutions, Peoria, Illinois, USA
  3. 3Sanofi Pasteur, Marcy l’Etoile, France
  4. 4Sanofi Pasteur, Lyon, France
  1. ↵*Corresponding author email: ruvim.izikson{at}gmail.com
Back to top
Posted October 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study
Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
medRxiv 2021.10.29.21265248; doi: https://doi.org/10.1101/2021.10.29.21265248
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area